Identification of differentially expressed genes in the kidneys of growth hormone transgenic mice

Growth Hormone and IGF Research

Volumn 20, Issue 5, 2010, Pages 345-355

  Coschigano, K T ^a,b   Wetzel, A N ^b   Obichere, N ^a   Sharma, A ^a   Lee, S ^a   Rasch, R ^c   Guigneaux, M M ^d   Flyvbjerg, A ^e   Wood, T G ^d   Kopchick, J J ^a,b  

^a OHIO UNIVERSITY   (United States)

^b OHIO UNIVERSITY   (United States)

^c AARHUS UNIVERSITY   (Denmark)

^d University of Texas Medical Branch School of Medicine   (United States)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CDNA subtraction; Chemokine (C C motif) ligand 2 monocyte chemotactic protein 1; Growth hormone transgenic mice; Immunoglobulins; Inflammation; Kidney; Kidney androgen regulated protein; Microarray; Real time RT PCR

Indexed keywords

ANDROGEN; COMPLEMENTARY DNA; GLYCOPROTEIN; GROWTH HORMONE; IMMUNOGLOBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA MICROARRAY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE LOCATION; INFLAMMATION; KIDNEY INJURY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; CATTLE; DOWN-REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLYCOPROTEINS; GROWTH HORMONE; IMMUNITY; IMMUNOGLOBULINS; KIDNEY; KIDNEY DISEASES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; UP-REGULATION;

EID: 77957116823     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2010.06.001     Document Type: Article

References (51)

1. Sen A., Buyukgebiz A. Albumin excretion rate, serum insulin-like growth factor-I and glomerular filtration rate in type I diabetes mellitus at puberty. J. Pediatr. Endocrinol. Metab. 1997, 10:209-215.
2. Cummings E.A., Sochett E.B., Dekker M.G., Lawson M.L., Daneman D. Contribution of growth hormone and IGF-I to early diabetic nephropathy in type 1 diabetes. Diabetes 1998, 47:1341-1346.
3. Doi T., Striker L.J., Quaife C., et al. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor-1. Am. J. Pathol. 1988, 131:398-403.
4. Yang C.W., Striker L.J., Pesce C., et al. Glomerulosclerosis and body growth are mediated by different portions of bovine growth hormone: studies in transgenic mice. Lab. Invest. 1993, 68:62-70.
5. Pesce C.M., Striker L.J., Peten E., Elliot S.J., Striker G.E. Glomerulosclerosis at both early and late stages is associated with increased cell turnover in mice transgenic for growth hormone. Lab. Invest. 1991, 65:601-605.
6. Yang C.W., Striker G.E., Chen W.Y., Kopchick J.J., Striker L.J. Differential expression of glomerular extracellular matrix and growth factor mRNA in rapid and slowly progressive glomerulosclerosis: studies in mice transgenic for native or mutated growth hormone. Lab. Invest. 1997, 76:467-476.
7. Ireland J.T., Patnaik B.K., Duncan L.J. Effect of pituitary ablation on the renal arteriolar and glomerular lesions in diabetes. Diabetes 1967, 16:636-642.
8. Merimee T.J., Fineberg S.E., Hollander W. Vascular disease in the chronic HGH-deficient state. Diabetes 1973, 22:813-819.
9. Chen N.Y., Chen W.Y., Bellush L., et al. Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology 1995, 136:660-667.
10. Chen N.Y., Chen W.Y., Kopchick J.J. A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin. Endocrinology 1996, 137:5163-5165.
11. Liu Z.H., Striker L.J., Phillips C., et al. Growth hormone expression is required for the development of diabetic glomerulosclerosis in mice. Kidney Int. Suppl. 1995, 5196039526:S37-S38.
12. Esposito C., Liu Z.H., Striker G.E., et al. Inhibition of diabetic nephropathy by a GH antagonist: a molecular analysis. Kidney Int. 1996, 50:506-514.
13. Flyvbjerg A., Bennet W.F., Rasch R., Kopchick J.J., Scarlett J.A. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy and urinary albumin excretion in experimental diabetes in mice. Diabetes 1999, 48:377-382.
14. Segev Y., Landau D., Rasch R., Flyvbjerg A., Phillip M. Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice. J. Am. Soc. Nephrol. 1999, 10:2374-2381.
15. Bellush L.L., Doublier S., Holland A.N., Striker L.J., Striker G.E., Kopchick J.J. Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice. Endocrinology 2000, 141:163-168.
16. Rotwein P., Chia D.J. Gene regulation by growth hormone. Pediatr. Nephrol. 2010, 25:651-658.
17. Chen W.Y., Wight D.C., Chen N.Y., Coleman T.A., Wagner T.E., Kopchick J.J. Mutations in the third alpha-helix of bovine growth hormone dramatically affect its intracellular distribution in vitro and growth enhancement in transgenic mice. J. Biol. Chem. 1991, 266:2252-2258.
18. Chen N.Y., Chen W.Y., Striker L.J., Striker G.E., Kopchick J.J. Co-expression of bovine growth hormone (GH) and human GH antagonist genes in transgenic mice. Endocrinology 1997, 138:851-854.
19. Machado M.O., Hirata R.D., Sellitti D.F., et al. Growth hormone promotes glomerular lipid accumulation in bGH mice. Kidney Int. 2005, 68:2019-2028.
20. Berryman D.E., List E.O., Coschigano K.T., Behar K., Kim J.K., Kopchick J.J. Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm. IGF Res. 2004, 14:309-318.
21. Coschigano K.T., Holland A.N., Riders M.E., List E.O., Flyvbjerg A., Kopchick J.J. Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology 2003, 144:3799-3810.
22. Flyvbjerg A., Dagnaes-Hansen F., De Vriese A.S., Schrijvers B.F., Tilton R.G., Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002, 51:3090-3094.
23. Hossenlopp P., Seurin D., Segovia-Quinson B., Hardouin S., Binoux M. Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal. Biochem. 1986, 154:138-143.
24. Altschul S.F., Madden T.L., Schaffer A.A., et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25:3389-3402.
25. Thomas R.P., Guigneaux M., Wood T., Evers B.M. Age-associated changes in gene expression patterns in the liver. J. Gastrointest. Surg. 2002, 6:445-453. discussion 454.
26. Lefever S., Vandesompele J., Speleman F., Pattyn F. RTPrimerDB: the portal for real-time PCR primers and probes. Nucleic Acids Res. 2009, 37:D942-D945.
27. Rozen S., Skaletsky H.J. Primer3 on the WWW for general users and for biologist programmers. Bioinformatics Methods and Protocols: Methods in Molecular Biology 2000, 365-386. Humana Press, Totowa, NJ. S. Krawetz, S. Misener (Eds.).
28. Andersen C.L., Jensen J.L., Orntoft T.F. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004, 64:5245-5250.
29. Meseguer A., Catterall J.F. Mouse kidney androgen-regulated protein messenger ribonucleic acid is expressed in the proximal convoluted tubules. Mol. Endocrinol. 1987, 1:535-541.
30. Wanke R., Wolf E., Hermanns W., Folger S., Buchmuller T., Brem G. The GH-transgenic mouse as an experimental model for growth research: clinical and pathological studies. Horm. Res. 1992, 37:74-87.
31. Wolf E., Wanke R. Growth hormone overproduction in transgenic mice: phenotypic alterations and deduced animal models. Welfare aspects of transgenic animals 1997, 26-47. Springer-Verlag, Berlin. L.F.M. Van Zutphen, M. van der Meer (Eds.).
32. Doi T., Striker L.J., Gibson C.C., Agodoa L.Y., Brinster R.L., Striker G.E. Glomerular lesions in mice transgenic for growth hormone and insulinlike growth factor-I. I. Relationship between increased glomerular size and mesangial sclerosis. Am. J. Pathol. 1990, 137:541-552.
33. Chen W.Y., Wight D.C., Wagner T.E., Kopchick J.J. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc. Natl Acad. Sci. USA 1990, 87:5061-5065.
34. Flyvbjerg A., Khatir D.S., Jensen L.J., Dagnaes-Hansen F., Gronbaek H., Rasch R. The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease. Curr. Pharm. Des. 2004, 10:3385-3394.
35. Ogueta S., Olazabal I., Santos I., Delgado-Baeza E., Garcia-Ruiz J.P. Transgenic mice expressing bovine GH develop arthritic disorder and self-antibodies. J. Endocrinol. 2000, 165:321-328.
36. Walport M.J. Lupus, DNase and defective disposal of cellular debris. Nat. Genet. 2000, 25:135-136.
37. Viedt C., Orth S.R. Monocyte chemoattractant protein-1 (MCP-1) in the kidney: does it more than simply attract monocytes?. Nephrol. Dial. Transplant. 2002, 17:2043-2047.
38. Frade J.M., Mellado M., del Real G., Gutierrez-Ramos J.C., Lind P., Martinez-A C. Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in B cells. J. Immunol. 1997, 159:5576-5584.
39. Reiser J., Mundel P. Danger signaling by glomerular podocytes defines a novel function of inducible B7-1 in the pathogenesis of nephrotic syndrome. J. Am. Soc. Nephrol. 2004, 15:2246-2248.
40. Uchio K., Sawada K., Manabe N. Expression of macrophage metalloelastase (MMP-12) in podocytes of hereditary nephrotic mice (ICGN strain). J. Vet. Med. Sci. 2009, 71:305-312.
41. Maecker H.T., Todd S.C., Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J. 1997, 11:428-442.
42. Yunta M., Rodriguez-Barbero A., Arevalo M.A., Lopez-Novoa J.M., Lazo P.A. Induction of DNA synthesis by ligation of the CD53 tetraspanin antigen in primary cultures of mesangial cells. Kidney Int. 2003, 63:534-542.
43. Gottfried E., Kunz-Schughart L.A., Weber A., et al. Expression of CD68 in non-myeloid cell types. Scand. J. Immunol. 2008, 67:453-463.
44. Keshav S., Chung P., Milon G., Gordon S. Lysozyme is an inducible marker of macrophage activation in murine tissues as demonstrated by in situ hybridization. J. Exp. Med. 1991, 174:1049-1058.
45. Klockars M., Reitamo S. Tissue distribution of lysozyme in man. J. Histochem. Cytochem. 1975, 23:932-940.
46. Urade Y., Ujihara M., Horiguchi Y., Ikai K., Hayaishi O. The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and kupffer cells in various rat tissues. J. Immunol. 1989, 143:2982-2989.
47. Rezende A.A., Semino-Mora C., Hirata M.H., et al. Up-regulation of toll-like receptors precedes matrix expansion in a model of growth hormone-induced glomerulosclerosis. American Society of Nephrology Renal Week 2006, TH-PO470. San Diego, CA (Abstract).
48. Anders H.J., Banas B., Schlondorff D. Signaling danger: toll-like receptors and their potential roles in kidney disease. J. Am. Soc. Nephrol. 2004, 15:854-867.
49. Cebrian C., Areste C., Nicolas A., et al. Kidney androgen-regulated protein interacts with cyclophilin B and reduces cyclosporine A-mediated toxicity in proximal tubule cells. J. Biol. Chem. 2001, 276:2949-29410.
50. Tornavaca O., Pascual G., Barreiro M.L., et al. Kidney androgen-regulated protein transgenic mice show hypertension and renal alterations mediated by oxidative stress. Circulation 2009, 119:1908-1917.
51. Fujimoto M., Maezawa Y., Yokote K., et al. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem. Biophys. Res. Commun. 2003, 305:1002-1007.